Astellas' XTANDItm (Enzalutamide) Granted European Commissio

Astellas' XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas' XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Barcelona , Comunidad Autonoma De Cataluna , Spain , Canada , Tokyo , United States , American , America , Ahsan Arozullah , Antonio Alcaraz , American Society Of Clinical Oncology , European Medicines Agency , Prnewswire Astellas Pharma Inc , European Commission , Committee For Medicinal Products Human Use , Head Of Oncology Development , European Association Of Urology , University Hospital Clinic Of Barcelona , Department Of Urology , Drug Administration , European Union , Astellas Pharma Inc , Granted European Commission Approval , European Association , University Hospital Clinic , Europa Uomo , Senior Vice President , Oncology Development , Medicinal Products , Human Use , Receives Positive , Medicines Agency Validates Type , Non Metastatic Hormone Sensitive Prostate Cancer , High Risk Biochemical , Pfizer Led Phase , South America , Important Safety Information , Product Characteristics , Focus Area Approach , Biochemically Recurrent Prostate , Clin Pract , Prostate Cancer ,